Global value of non-oral drug self-administration to exceed $130 billion in 2014
This forecast is based on the analysis of more than two dozen therapeutic segments that also found the number of non-oral pipeline candidates increasing after a temporary decline.
Greystone said that growth in non-oral self-delivery is being propelled by four important factors, an increase in the number of approved biological drugs that present significant challenges to oral formulations and the second factor is the added cost and strain on the healthcare system associated with patient visits to caregivers for drug treatments.
The third factor is the availability of patient-friendly delivery methods and the last factor is the desire by patients to avoid routine caregiver visits.
As drug delivery and formulation technology advance, the trend toward self-administration will impact a wider range of drug classes and disease indications. Greystone’s analysis indicates that the number of therapeutic segments dominated by self-administration will increase from eight in 2009 to eleven in 2014.
George Perros, managing director of Greystone Research Associates, said: “As the dynamics of patient populations and disease prevalence evolve for a growing list of conditions, the underlying healthcare economics and the logistical realities of caregiver accessibility are expected to become highly unfavorable. In this environment the benefits of patient drug self-administration are becoming more compelling.
“The escalating sophistication of devices and delivery methods targeting patient self-administration continues to create opportunities for an expanding supply chain infrastructure and ecosystem, particularly for CSOs specializing fill-and-finish, testing and packaging.”
Have your say and discuss with your peers on the InfoGrok community.
Participate by posting your comments now.